Actively Recruiting
Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-03-31
60
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Brain metastases are common in cancer patients, especially those with lung cancer, which frequently spreads to the brain. This research aims to compare the diagnostic accuracy of a new MRI technique called the CEST sequence against the standard T2* infusion method with contrast injection. The goal is to improve how doctors distinguish between tumor growth and radionecrosis, a late side effect of radiotherapy occurring in brain metastases from lung cancer. Participants will undergo MRI scans that include three special sequences: CEST, IVIM, and ASL. These sequences add about 10 minutes to the scanning time and do not require contrast injection for the CEST method. The study involves patients who have received radiotherapy for brain metastases and shows growth of these lesions on follow-up MRI. The study will evaluate diagnostic performance over 24 months, including blood flow mapping and tissue characterization. During the study, patients will have regular MRI scans using these sequences. Researchers will measure brain blood flow, tissue molecular content, and changes in white matter within and outside the radiation field. They will also monitor how well patients tolerate the MRI procedures. The main outcome is detecting hyperperfusion in brain metastases, with follow-up lasting up to two years to assess diagnostic accuracy and safety.
CONDITIONS
Brief Title
Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years
- Histologically confirmed primary lung cancer
- Histologically confirmed or suspected brain metastases
- Metastases treated with radiotherapy
- Enrolled in a treatment protocol involving whole brain or stereotactic radiosurgery for brain metastases
- Morphological increase of one or more secondary brain metastases on follow-up MRI
- Affiliated to a social security scheme
You will not qualify if you...
- Patient opposition to participating in the study
- Contraindication to MRI
- Refusal of imaging by the patient
- Patients with state medical aid unless exempt from affiliation
- Severe cognitive impairment preventing informed consent
- Patients under guardianship or deprived of liberty
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single session lasting approximately 10 minutes longer than standard MRI
Participants undergo specialized MRI sequences including CEST, IVIM, and ASL to characterize radionecrosis and tumor progression of brain metastases.
1 imaging visit (in-person)
Duration - Up to 24 months
Participants are monitored for up to 24 months to assess changes in brain metastases and treatment effects through follow-up imaging and evaluations.
Follow-up visits as per standard clinical care and imaging schedules
Trial Site Locations
Total: 1 location
1
Hôpital Bichat-Claude Bernard
Paris, France, 75018
Actively Recruiting
Research Team
A
Augustin Gaudemer, MD
M
Marie-Cécile Henry-Feugeas, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here